Remifentanil for General Anesthesia in Preeclamptics

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to determine whether remifentanil use in preeclamptic patients may blunt hemodynamic response to intubation during general anesthesia for cesarean section.

Clinical Trial Description

General anesthesia for cesarean section involves rapid sequence induction with a muscle relaxant and barbiturate followed by endotracheal intubation. Although the use of opioids may blunt haemodynamic responses to endotracheal intubation, they are avoided in pregnant patients due to possible respiratory depressants effects on neonates.Preeclamptic patients response with exaggerated sympathoadrenal reflex to anesthesia induction and intubation. The resulting hypertension and tachycardia may result in cerebrovascular accident, pulmonary edema, arrhythmias, increased myocardial oxygen consumption and fetal hypoxia by uterine vasoconstriction. Several drugs have been used to blunt the hemodynamic disturbances to intubation, but none of them have been implicated for routine use for general anesthesia in preeclamptic patients.

Recently remifentanil has started to be used in general anesthesia of high risk obstetric patients. Remifentanil is a μ-opioid receptor agonist that is metabolized by nonspecific blood and tissue esterase hydrolysis. It has a low distribution volume with a context sensitive half life of 3 minutes. Its elimination half life is 12 minutes even after repeated boli. Previously remifentanil use in pregnant patients with cardiac pathology has been reported with minimal neonatal side effects. A randomized controlled study in normal parturient has shown that remifentanil is transferred through placenta and may cause mild neonatal depression that is easily managed. Umbilical artery and vein remifentanil concentrations has shown that remifentanil is quickly redistributed or metabolized in fetus. Thus, remifentanil may be an appropriate drug for induction and maintenance of general anesthesia in severe preeclamptic patients. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00567957
Study type	Interventional
Source	Istanbul University
Contact	Tulay Ozkan Seyhan, Associate Prof.
Phone	+90 212 631 87 67
Email	tulay2000@e-kolay.net
Status	Not yet recruiting
Phase	Phase 4
Start date	February 2008
Completion date	December 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03299777` - Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan	N/A
Completed	`NCT03650790` - C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies	N/A
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Not yet recruiting	`NCT03302260` - Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial	N/A
Completed	`NCT02911701` - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features	Phase 4
Completed	`NCT01911494` - Community Level Interventions for Pre-eclampsia	N/A
Terminated	`NCT02025426` - Phenylephrine Versus Ephedrine in Pre-eclampsia	Phase 4
Completed	`NCT01352234` - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia	Phase 4
Active, not recruiting	`NCT02031393` - Establishing First Trimester Markers for the Identification of High Risk Twin	N/A
Terminated	`NCT00141310` - Sildenafil Citrate for the Treatment of Established Pre-Eclampsia	Phase 2
Completed	`NCT00157521` - L-Arginine in Pre-Eclampsia	Phase 3
Completed	`NCT04795154` - Prenatal Yoga as Complementary Therapy of Preeclampsia	N/A
Completed	`NCT00004399` - Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia	N/A
Completed	`NCT00005207` - Renin and Prorenin in Pregnancy	N/A
Recruiting	`NCT04551807` - Natural Versus Programmed Frozen Embryo Transfer (NatPro)	Phase 3
Terminated	`NCT04092829` - Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer	N/A
Recruiting	`NCT06067906` - Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients	N/A
Recruiting	`NCT06317467` - Role of Anti-C1q Autoantibodies in Pregnancy
Completed	`NCT02218931` - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes	N/A
Active, not recruiting	`NCT04484766` - Preeclampsia Associated Vascular Aging

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.